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Abstract Infection of hepatitis C virus (HCV) is associated
with primary hepatocellular carcinoma (HCC). However, its
underlying molecular mechanisms remain enigmatic. Tumor
necrosis factor-α-induced protein 8-like 2 (TIPE2), a new
negative regulator of immunity, plays significant roles in mod-
ulating inflammation and tumorigenesis. We hypothesized
that TIPE2 might be involved in the development of HCV-
induced HCC. To test this hypothesis, the expression of TIPE2
was determined by Western blot in the tumor and
pericarcinomatous tissues collected from ten HCV-positive
HCC patients; the interaction between TIPE2 and HCV-
encoded non-structural proteins was analyzed by immunopre-
cipitation and immunofluorescence assays, and tumorigenesis
and its mechanisms were studied in cell models and nude
mice. Our results demonstrated that the expression of TIPE2
was significantly reduced in HCC tissues compared to that in
the paracarcinoma tissues. HCV-encoded non-structural
protein NS5A could specifically interact with TIPE2 and in-
duce its degradation. Downregulation of TIPE2 by shRNA in
cell lines increased genomic DNA damage and promoted cell
colony formation in vitro and tumorigenesis in nude mice. In
contrast, overexpression of TIPE2 had an opposite effect.
Downregulation of TIPE2 by NS5A is associated with geno-
mic DNA instability and HCV-induced HCC development.
Thus, TIPE2 may be a new therapeutic target for the treatment
of HCV-associated HCC.
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HCC Hepatocellular carcinoma
HCV Hepatitis C virus
DDR DNA damage response
TIPE2 Tumor necrosis factor-α-induced protein-8 like-2
ROS Reactive oxidative stress
NOS Nitric oxide synthase
Introduction
Currently, there are more than 150 million hepatitis C virus
(HCV)-infected individuals in the world [1]. Chronic HCV
infection is highly associated with hepatocellular carcinoma
(HCC). HCC is the most common histological subtype of
primary liver carcinoma and accounts for 70–85 % of total
liver cancers [1, 2], and almost half of the patients are from
China [3].
HCV, a sense-strand RNAvirus, replicates exclusively in the
cytoplasm and is unable to integrate into the host genome; the
underlying mechanisms of HCV-induced hepatocarcinogenesis
Yaohui Wang, Yinan Jiang, and Jinxue Zhou contributed equally
* Yuanfang Ma
mayf@henu.edu.cn
1 Henan Key Laboratory of Engineering Antibody Medicine, Medical
College of Henan University, Kaifeng, Henan 475004, China
2 College of Basic Medical Sciences, Zhengzhou University,
Zhengzhou, Henan 450001, China
3 Zhengzhou University Affiliated Tumor Hospital,
Zhengzhou, Henan 450001, China
4 Key Laboratory of Medical Molecular Virology, School of Basic
Medical Sciences, Shanghai Medical College, Fudan University,
Shanghai, China
5 Department of Pathology and Laboratory Medicine, University of
Pennsylvania Perelman School of Medicine, Philadelphia,
PA 19104, USA
Tumor Biol. (2016) 37:15265–15274
DOI 10.1007/s13277-016-5409-z
remain elusive. Among the ten HCV encoded structural (core,
E1, E2) and non-structural (P7, NS2, NS3, NS4A, NS4B,
NS5A, NS5B) proteins [4], core, NS3, NS4B, and NS5A have
been shown to directly activate oncogenic molecular pathways
and promote tumor formation in vivo [5–8]. The strategies
employed by HCV and encoded proteins to induce tumor for-
mation include chronic inflammation, reactive oxidative stress
(ROS), steatosis, fibrosis, and so on. DNA damage/repair is
associated with almost all of the above pathogenic patterns. In
fact, core, NS3/4A, NS5A, and NS5B have been reported to
enhance DNA damage or suppress damage repair [9–13].
Consistently, in HCC patients, accumulation of DNA damage
has been detected in the peripheral blood lymphocytes [14] and
abundant H2AX+ T lymphocytes were found in the liver [15].
Tumor necrosis factor-α-induced protein-8 like-2 (TIPE2
or TNFAIP8L2) is a newly identified protein essential for the
maintenance of immune homeostasis [16]. The crystal struc-
ture of TIPE2 revealed a large hydrophobic central cavity as
the binding sites for cofactors [17]. Apart frommaintenance of
immune homeostasis, TIPE2 inhibits Ras activity via binding
RalGDS and thereafter suppresses Ras-induced tumorigenesis
in mice [18]. Downregulation of TIPE2 is associated with
poor prognosis of non-small cell lung cancer, and it can also
inhibit HCC cell metastasis [19, 20]. A recent study showed
that expression of TIPE2 was reduced in peripheral blood
mononuclear cells and tumor tissues from HBV-infected pa-
tients compared to healthy individuals [21]. Interestingly,
TIPE2 was also shown to negatively regulate oxidative burst,
indicating a possible involvement of DNA damage in the
TIPE2-mediated tumorigenesis [22]. However, whether
TIPE2 and TIPE2-mediated DNA damage are involved in
HCV-related HCC is still unknown.
In the present study, we investigated the association be-
tween TIPE2 and HCV-related HCC at clinical specimen, cell
culture, and animal model aspects. The results showed that
expression of TIPE2 is significantly reduced in tumor tissues
compared to that in the paracarcinoma tissues from HCV-
positive HCC patients. HCV/NS5A interacts with TIPE2
and promotes its degradation. Ectopic expression of TIPE2
can reduce DNA damages, while silencing TIPE2 with small
hairpin (shRNA) can enhance it. Upregulation of TIPE2 can
inhibit the HCC’s tumor characteristics. These results suggest
that TIPE2 is a negative regulator of HCV-associated HCC.
Materials and methods
Clinical specimens
This study was approved by the Ethics Committees of the
Medical College of Henan University, and written informed
consent was obtained from all participants. Tumor and
pericarcinomatous liver tissues were collected from ten
HCV-positive HCC patients at the Affiliated Tumor Hospital
of Zhengzhou University. The tissues were frozen at −80 °C,
and protein was extracted by radioimmunoprecipitation
(RIPA) tissue lysis buffer after grinding in liquid nitrogen.
Patients’ clinical characteristics are presented in Table 1.
Animals and cells
The animal experiments performed in this study were prior
approval by the Animal Experimentation Committee of
Henan University. Four-week-old male BALB/cA-nu mice
were purchased from Beijing HFK Bioscience. All mice re-
ceived standard diet and water and were treated in accordance
with the National Guide for the Care and Use of Laboratory
Animals. The cell lines HEK293T, Changliver, and Huh7 cells
were maintained in DMEMmedium supplemented with 10 %
fetal bovine serum, 2 mM L-glutamine, and penicillin
(100 units/ml)-streptomycin (100 μg/ml).
Antibodies and reagents
Mouse anti-Chk1, rabbit anti-Chk2, anti-H2AX, anti-
phospho-Chk1, anti-phospho-Chk2, and anti γ-H2AX anti-
bodies were purchased from Cell Signaling Technology
(Danvers, USA). Mouse monoclonal anti-β-actin and anti-
FLAG were purchased from Sigma (St. Louis, USA), and
rabbit anti-TIPE2 was purchased from Boster (Wuhan,
China). Puromycin, crystal violet, MTT, DMSO, and bovine
serum albumin (BSA) were purchased from Sigma, and
DMEM medium and fetal bovine serums were purchased
from Gibco (Gran Island, USA). Lentiviral vector pLKO.1,
psPAX2, and pMD2.G were obtained from Addgene.
Transfection and establishment of stable cell lines For tran-
sient transfection, the cells were inoculated overnight and
reached to 60–70 % confluence; a certain amount of plasmid
DNA was transiently transfected into the cells with the X-
tremeGENEHPDNA transfection reagent following the man-
ufacturer’s protocol (Promega, Madison, USA). The cells
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to the indicated experiments. To generate stable cell lines, the
Changliver cells were transduced with lentiviral particles con-
taining either TIPE2 shRNA or scramble shRNA. For ectopic
expression of TIPE2, the Huh7 cells were infected with
lentiviral particles expressing TIPE2 cDNA or empty vector.
The cells were selected in 2 μg/ml puromycin for 2 weeks and
were pooled for future study.
Cell proliferation and plate colony formation assay
For plate colony formation assay, cells were detached and
seeded in six-well plates with 500 cells per well in culture
medium. Twoweeks later, visible clone cell clusters appeared.
The cells were washed twice with PBS and fixed in 4 % para-
formaldehyde for 15 min followed by staining with crystal
violet for 20 min. The cells were then washed with PBS and
air-dried. The colony is quantified and photographed under
microscopy. The colony number divided by total cell numbers
accounts for the colony formation rate. For cell viability, the
cells were seeded in 96-well plates at a density of 5 × 103 cells
per well, and cell growth curve was measured by MTT assay.
DNA damage model in vitro
To construct DNA damage cell model, the cells were seeded
into 12-well plates; 24 h later, culture medium was changed
with fresh medium containing hydroxyurea or DMSO at
3 mM and incubated for another 24 h. Cell lysates were then
collected for immune blotting analysis.
Immunoblotting analysis and co-immunoprecipitation-
Cells were lysed with RIPA buffer containing protease inhib-
itor cocktail, and protein concentration was determined using
bicinchoninic acid reagent (CWBIO, Beijing, China). Equal
amounts of protein were loaded in each well for electropho-
resis followed by transferring onto nitrocellulose filter mem-
brane. After blocking with 5 % fat-free milk or 5 % BSA, the
membranes were incubated with primary antibodies overnight
at 4 °C. After washing in Tris-buffered saline and Tween
(TBST) buffer for three times, the membranes were incubated
with HRP-conjugated secondary antibody for 1 h at room
temperature. Then, the membranes were washed in TBST
for three to four times, and then, they were developed in
ECL buffer for 2 min. The signals were measured by exposing
to the X-ray film. For co-immunoprecipitation, the cells were
lysed in immunoprecipitation (IP) lysis buffer containing pro-
tease and phosphatase inhibitors. About 1 mg proteins were
incubated with proper primary antibody at 4 °C overnight
(control IgG is used as negative control). Fifty microliters of
50 % slurry protein A-agarose beads was added to the cell
lysates for 2 h. The protein A-agarose beads were pelleted
and washed in TBST buffer for five times. The proteins that
are eluted from protein A-agarose beads were subjected to the
immunoblotting. For glutathione S-transferase (GST) pull-
down assay, the cells were lysed in the IP lysis buffer. The
equal amounts of lysated proteins were incubated with GST
alone or GST-TIPE2 proteins that were purified from bacteria
at 4 °C overnight. Fifty microliters of glutathione Sepharose
4b beads was added to the protein lysates and incubated for
1 h at 4 °C. The beads were pelleted and washed for five times
in cell lysis buffer. The eluted proteins were subjected to the
immunoblotting.
Immunohistochemistry and immunofluorescence assay
For histology, tumor tissues were fixed with 4 % paraformal-
dehyde at 4 °C overnight for paraffin embedding. After
dewaxing, the slides were incubated in 3 % H2O2 for 20 min
to block endogenous peroxidase. Antigen retrieval was done
at 95 °C for 20 min with citric acid hydrochloric acid antigen
retrieval buffer. Tissue sections were incubated with blocking
buffer containing 5 % BSA for 30 min and then subsequently
with primary and secondary antibodies. SABC (BOSTER,
Wuhan, China) was utilized to amplify signal before hema-
toxylin and AEC or DAB (ZSGB-BIO, Beijing, China)
staining.
Cells grown on glass coverslips were analyzed with immu-
nofluorescence assay as previous [13]. Briefly, the cells were
fixed with 4 % paraformaldehyde and permeabilized with
0.4 % Triton X-100. After blocking with 3 % BSA, the cells
were incubated with primary antibodies and subsequently
with fluorescein isothiocyanate (FITC)-labeled secondary an-
tibodies. Coverslips were mounted with Prolong Gold Anti-
fade Reagent (containing DAPI, Thermo, Hudson, USA). The
signals were observed and photographed under the confocal
microscopy (Nikon, ECLIPSE Ti).
Tumor models
Four-week-old male BALB/cA-nu mice were injected subcu-
taneously in the right underarms with Huh7 stable cells and
Changliver stable cells (5 × 106 cells per 100 μl). After inoc-
ulation, tumor growthwasmonitored daily for 2–4weeks with
a vernier caliper until the tumor size reached approximately
100 mm3. Mice were sacrificed by spinal cord dislocation for
tumor collection and subsequent detection at indicated time.
TUNEL staining
For TUNEL staining, mouse sh-TIPE2 tumor tissue and sh-
Ctrl/TIPE2 Huh7 cells were fixed with 4 % paraformalde-
hyde, permeabilized with 0.1 % Triton X-100, and stained
with TUNEL labeling solution (Roche, Switzerland) accord-
ing to the manufacturer’s instructions.
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Results
Downregulation of TIPE2 in tumor tissues
of HCV-positive HCC
To study the roles of TIPE2 in HCV-associated HCC,
the expressions of TIPE2 in the HCV-positive HCC tis-
sues were measured by immunoblotting. Ten HCV-
positive HCC and their paracarcinoma tissues were ap-
plied to immunoblotting. As indicated in Fig. 1, the
expression of TIPE2 is significantly reduced in eight
of ten HCV-positive HCC tissues compared to that in
the tissues adjacent to the HCC tissues (Fig. 1a). To
exclude the contamination of other tissues or immune
cells, immunohistochemistry was performed to confirm
the downregulation of TIPE2 in hepatocyte (Fig. 1b).
Similarly, lower level of TIPE2 was observed in the
hepatoma cell lines such as Huh7 and HepG2 cells
compared to non-cancer Changliver cells (data not
shown). These results suggested that TIPE2 is involved
in HCV-associated HCC.
HCV non-structural protein NS5A promotes TIPE2
degradation
HCV promotes HCC development via encoding a number
of oncoproteins such as Non-structural proteins NS3/4A,
NS5A, and NS5B. To determine whether downregulation
of TIPE2 in HCV-positive HCC tissue (Fig. 1) is regulat-
ed by HCV non-structural proteins, TIPE2 was transiently
co-expressed with NS3/4A, NS5A, or NS5B in 293T
cells. The immunoblotting results indicated that NS5A
could significantly reduce TIPE2 protein expression level
(Fig. 2a) in a dose-dependent manner (Fig. 2b).
Furthermore, the downregulation of TIPE2 could be re-
versed by proteasome inhibitor, MG132 (Fig. 2c), which
suggested that the degradation of TIPE2 induced by
NS5A is proteasome dependent.
NS5A interacts with TIPE2
Since NS5A could reduce TIPE2 expression, we predict
that there may be interactions between them. To test this
Fig. 1 Downregulation of TIPE2
in HCV-positive HCC tumor
tissues. Representative
photographs of TIPE2 protein
expression in HCV-positive HCC
tissues (Ca) and adjacent liver
tissues (N) examined by Western
blot (a) and IHC (b) with anti-
TIPE2 antibody. Positive cells
were stained in brown. Scale
bars = 200 μm
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hypothesis, we constructed GST and GST-TIPE2 expres-
sion plasmids and expressed them in prokaryotic BL21
cells. The GST pull-down assay (Fig. 3a) revealed that
TIPE2 was strongly associated with NS5A but hardly
with NS5B or NS3/4A (Fig. 3a).
To further confirm the interaction between TIPE2 and
NS5A, co-IP of myc-TIPE2 and FLAG-NS5A with anti-
FLAG antibody was performed. The result demonstrated a
strong interaction between TIPE2 and NS5A (Fig. 3b). co-IP
of FLAG-TIPE2 and myc-NS5A showed similar results
(Fig. 3c). co-IP from Huh7 cells indicated that the interaction
also exists in hepatoma cells (Fig. 3d).
To visualize the co-localization of TIPE2 and NS5A in
situ, we co-transfected GFP-TIPE2 and myc-NS5A plas-
mids into 293T cells. Confocal microscopy revealed an ob-
vious co-localization of TIPE2 and NS5A in cytoplasm
(Fig. 4a). The co-localization of TIPE2 and NS5Awas also
observed in Huh7 cells (Fig. 4b). Collectively, we conclud-
ed that NS5A binds TIPE2 and possibly leads to degrada-
tion of TIPE2.
TIPE2 inhibits the DDR in vitro
Cancer development is accompanied with continuous
DNA damage. We therefore speculated that TIPE2 might
be involved in DNA damage/repair. To determine whether
TIPE2 is involved in tumor’s DNA damage/repair, we
generated Huh7-TIPE2-overexpressing stable cell line
and Changliver-TIPE2 knockdown stable cell line by
using lentivirus infection. The cells were left without
treatment or treated with hydroxyurea (HU) for inducing
DNA damage. The results indicated that ectopic expres-
sion of TIPE2 could reduce the phosphorylation level of
H2AX, Chk1, and Chk2 in Huh7-TIPE2 cells (Fig. 5a). In
contrast, the phosphorylation level of H2AX, Chk1, and
Chk2 was much elevated in Changliver-TIPE2 knock-
down cells (Fig. 5b). Consistently, we also observed the
increase of TUNEL-positive cells in mice sh-TIPE2 tumor
tissue and Huh7 stable cells (Fig. 5c). These results
indicate that TIPE2 directly induces DNA damage and
diminishes HU-induced DNA damage response.
TIPE2 suppressed hepatocellular tumorigenesis in vitro
and in vivo
To examine the potential roles of TIPE2 in the inhibition
of HCC tumor growth, we performed plate colony forma-
tion assay using Huh7-TIPE2 overexpression and
Changliver-TIPE2 knockdown stable cell lines in vitro.
As shown in Fig. 6a, almost no clone was formed by
the Huh7-TIPE2-overexpressing cells. However, colony
formation efficiency of Changliver-TIPE2 knockdown
cells was significantly higher than that of the control cells.
The results of Huh7-TIPE2 and Changliver-TIPE2 knock-
down xenografts in nude mice suggest that the tumor vol-
ume and growth speed of Huh7-TIPE2 overexpression
cells are much reduced compared to Huh7 itself
(Fig. 6b–d). In contrast, the tumor growth and tumor vol-
ume derived from the Changliver-TIPE2 knockdown cells
are much increased compared to the tumors of Changliver
cells itself (Fig. 6b–d). Furthermore, we also observed the
higher viability in TIPE2 stable Huh7 cells after NS5A
overexpression (Fig. 6e). These results suggest that
TIPE2 may negatively regulate HCC tumorigenesis.
TIPE2 inhibits DDR in tumor
To determine the molecular mechanism underlying the TIPE2
effect, we studied DNA damage response (DDR) in the tu-
mors derived from the nude mice by immunohistochemistry.
Fig. 2 HCV-encoded NS5A leads to TIPE2 degradation. a HEK293T
cells were incubated in 12-well plate; when the confluence is up to 70 %,
cells were transiently co-transfected with TIPE2 (0.5 μg) and equal
amount of HCV NS5A, NS5B, NS3/4A, or vector plasmids as
indicated. Forty-eight hours post-transfection, expression of TIPE2 was
determined by Western blot. b TIPE2 was co-transfected into 293T cells
with increasing amounts of NS5A plasmids. Forty-eight hours later, cell
lysates were subjected to SDS-PAGE and analyzed by Western blot. c
TIPE2 was co-transfected into 293T cells with increasing amounts of
NS5A plasmids. Cells were treated with DMSO or 1 mM MG132 6 h
before harvesting. Forty-eight hours post-transfection, cell lysates were
subjected to SDS-PAGE and analyzed by Western blot
Tumor Biol. (2016) 37:15265–15274 15269
As shown in Fig. 7a, the expression of γ-H2AX is much
higher in the tumor tissue generated from Huh7 cells
(Huh7-vector) than that in the Huh7-TIPE2 tumor tissues.
In contrast, the immunohistochemistry staining of γ-
Fig. 4 Co-localization of TIPE2
and NS5A in cytoplasm. Myc-
NS5As were co-transfected into
293T cells (a) or Huh7 cells (b)
with EGFP or EGFP-TIPE2
plasmids, respectively. After 48 h,
the cells were fixed, stained, and
analyzed with confocal
microscopy
Fig. 3 Interaction between TIPE2 and NS5A. a The association of
TIPE2 with NS5A, NS5B, or NS3/4A was detected by GST pull-down
assay, and Coomassie Brilliant Blue staining of TIPE2 expressed in
prokaryotic expression cells (BL21) was shown. b Myc-TIPE2 was
transiently co-transfected into 293T cells with FLAG-NS5A or FLAG-
NS5B. Cell lysates were co-immunoprecipitated with anti-myc antibody
or isotype IgG followed by Western blot. c 293T cells were transiently
transfected with FLAG-TIPE2 and myc-NS5A. The cell lysates were co-
immunoprecipitated with anti-FLAG antibody or isotype IgG followed
by Western blot. d Huh7 TIPE2 stable cells were seeded into 10-cm dish
and transfected with 6 μg myc-NS5A plasmids, and 48 h later, co-IP was
performed as above
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H2AX is much stronger in Changliver-TIPE2 knockdown
tumors than that in the tumors generated from parental
Changliver cell (Fig. 7b). These results strongly suggest
that TIPE2 can inhibit tumorigenesis by suppressing the
DNA damage response.
Discussion
TIPE2 is a newly identified regulator of immunity, while
emerging evidence indicates that TIPE2 might be also a
novel tumor suppressor. We therefore hypothesized that
TIPE2 might be employed by cancer-causing pathogens,
such as HBV and HCV, to initiate tumorigenesis or pro-
mote tumor growth. Intriguingly, recent studies have re-
ported that TIPE2 expression was decreased in the periph-
eral blood mononuclear cells (PBMCs) of patients with
chronic hepatitis B and in HBV-related HCC tumor tissue
[21, 23]. Compared to HBV, HCV infection is more strongly
associated with cirrhosis, hepatic decompensation, and HCC
[1]. In the present study, for the first time, we observed down-
regulation of TIPE2 in the HCV-positive HCC tissue from a
cohort of patients. These data suggest that TIPE2 is a common
pathway of virus-induced HCC development.
While downregulation of TIPE2 was noticed in HCC
tissue, the mechanisms underlying it remain unknown. In
the current study, we found that one of the HCV-encoded
non-structural proteins NS5A was adversely associated
with the expression of TIPE2. This suggests that NS5A
leads to degradation of TIPE2. There are mainly two path-
ways leading to protein downregulation: transcriptional
regulation and protein modification. Interestingly, no sig-
nificant difference was observed at mRNA level of TIPE2
between HBV-related HCC and its adjacent non-tumor
tissue, while obviously higher level of ubiquitination of
TIPE2 was detected and the proteasome inhibitor MG132
could restore TIPE2 protein accumulation [18]. Those da-
ta suggest that TIPE2 was degraded at protein level in
HCC. We also found that TIPE2 could be restored by
MG132 at the presence of NS5A. The mechanism by
Fig. 5 Downregulation of TIPE2
stimulates DNA damage
response. a TIPE2-
overexpressing stable cell line and
control cell line were treated with
hydroxyurea or DMSO as
indicated. Cell lysates were
collected and analyzed for
phospho-H2AX, Chk1, and Chk2
levels with Western blot. b sh-
TIPE2 and corresponding sh-Ctrl
stable cell lines were exposed to
hydroxyurea or DMSO, and then,
the phospho-H2AX, Chk1, and
Chk2 levels were determined by
Western blot. c TUNEL staining
was performed in mice sh-TIPE2
tumor tissue and Huh7 sh-TIPE2
stable cells. Green: TUNEL-
positive cells
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which NS5A induces the degradation of TIPE2 is not
clear and needs further investigation.
Reactive oxygen species (ROS) and the products of induc-
ible nitric oxide synthase (NOS) generated upon HCV infec-
tion could lead to DNA damage [9, 24]. HCV-encoded core,
NS2, NS3/4A, and NS5B have been reported to trigger DNA
damage. There have been also several studies that revealed
association between NS5A and genomic instability via ROS.
High level of ROS could be induced by NS5A in transgenic
mice, cooperated with upregulation of NF-κB and STAT3,
which promote steatosis and HCC [25]. NS5A also reduced
tumor suppressor PTEN expression in ROS-dependent path-
way [26]. In fact, NS5A is associated with chromosomal insta-
bility and mitotic cell cycle dysregulation [10]. Interestingly,
NS5A was recently shown to downregulate the growth arrest
and DNA damage-inducible gene 45-α (GADD45α)
Fig. 6 TIPE2 suppresses
hepatocellular tumorigenesis
in vitro and in vivo. a TIPE2-
overexpressing, TIPE2 silencing,
and control cells were utilized for
the plate colony formation assay,
respectively. b Isolated tumors
from mice injected with control,
TIPE2-overexpressing, or TIPE2
silencing cells. c The average
weights of isolated tumors in b
were quantified. d The growth
curves of subcutaneous tumors
from themice. eCell viability was
measured up to 48 h by MTT
assay in TIPE2 stable expressing
Huh7 cells after transient
transfection with NS5A and
control plasmids. *p < 0.05
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expression [27]. In this study, we showed that NS5A reduced
TIPE2 expression and consequently induced DNA damage re-
sponse. Activation of DNA damage response may result in
impairment of damage repair, dysregulation of cell cycle, apo-
ptosis, or tumor formation. Previous investigation has demon-
strated that tumor is developed spontaneously in NS5A trans-
genic mice [28]. Our findings provide further evidence and
molecular mechanism for the oncogenic effect of NS5A.
The connection between TIPE2 and DNA damage is
surmisable according to the existing data. During infection,
TIPE2 could inhibit phagocytosis and oxidative burst by
binding to and blocking Rac GTPases [22]. Rac was re-
ported to stimulate DDR. Furthermore, Rac1 was sug-
gested responsible for the genotoxin-induced DNA dam-
age in the liver [29]. On the other hand, Rac-mediated
nuclear mechanisms are required for activation of DDR
following topo II poison challenge in a p53- and heat shock
protein-independent pathway [30]. So we predict that the
upregulation of γ-H2AX, pChk1, and pChk2 in TIPE2
deficiency cells and HCC tumor tissue indicates that
TIPE2 inhibits DDR during virus infection likely via the
Rac pathway. Taken together, we propose that TIPE2 is
centralized in a pathogenic network of infection, inflam-
mation, DNA damage, and tumor formation.
In summary, our work suggests that HCV promotes HCC
development via DNA damage, through downregulation of
TIPE2 by its encoded NS5A protein. Our study provides a
novel mechanism underlying HCV-related HCC development
and identifies TIPE2 as a potential therapeutic target for HCV-
related HCC.
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Fig. 7 DNA damage in tumor
tissues generated in the nude
mice. Expression of γ-H2AX in
the tumor tissues isolated from the
mice injected with Huh7-TIPE2
and control cells (a) or Changliver
sh-TIPE2 and control cells (b).
Positive cells were stained in red
in the nuclei. Scale bars = 50 μm
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